<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04764500</url>
  </required_header>
  <id_info>
    <org_study_id>2019-00044; am21Egli</org_study_id>
    <nct_id>NCT04764500</nct_id>
  </id_info>
  <brief_title>Developing Microbials to Fight Extended-spectrum Beta-lactamase (ESBL)-Producing Escherichia Coli</brief_title>
  <official_title>Developing Microbials to Fight Extended-spectrum Beta-lactamase (ESBL)-Producing Escherichia Coli</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gebert Rüf-Stiftung</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to identify and isolate well-defined microbials (non-ESBL E. coli) in an&#xD;
      observational setting exploring natural gastrointestinal decolonization of humans colonized&#xD;
      with ESBL E. coli.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Antibiotic resistance is a severe threat to contemporary medicine. Effective approaches to&#xD;
      fight multi-drug resistant pathogenic bacteria are needed.&#xD;
&#xD;
      This clinical observational study is to investigate whether express extended spectrum beta&#xD;
      lactamases (ESBL) E. coli colonizing the human gut can be out-competed by other, ideally&#xD;
      pan-sensitive strains (non-ESBL E. coli).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 13, 2019</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Actual">February 9, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of patients being &quot;naturally&quot; decolonized from ESBL E. coli</measure>
    <time_frame>18 months</time_frame>
    <description>proportion of patients being &quot;naturally&quot; decolonized from ESBL E. coli at the end of the study period at 18 months</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">39</enrollment>
  <condition>Extended Spectrum Beta Lactamases (ESBL) E. Coli</condition>
  <arm_group>
    <arm_group_label>travellers to Southeast Asia</arm_group_label>
    <description>Clients planning to travel to Southeast Asia will be recruited</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>examination of stool sample</intervention_name>
    <description>Each participant provides stool samples before and after travelling, after 2, 4, 6, 8, 10, 12, 16, 20 and 52 weeks. Stool samples will be used for isolating both a) ESBL E. coli strains and b) pan-sensitive E. coli strains. Part of the stool sample is stored for isolation of further E. coli clones and microbiota analysis of the isolation of other microbiota strains. All found Enterobacteriaceae will be screened for additional resistance such as Carbapenem and Colistin. In case of a specific resistance, this will be confirmed with additional phenotypic and genotypic tests such as ROSCO disk and polymerase chain reaction (PCR) based panel and whole genome sequencing in order to detect specific resistance mechanisms and genes. Bacteria will be sequenced using Illumina and Nanopore based sequencing. Bioinformatic analysis will allow to determine the whole bacterial genome with containing resistance genes and also describe the microbiota diversity over time in single individuals.</description>
    <arm_group_label>travellers to Southeast Asia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>patient questionnaire</intervention_name>
    <description>Each participant will have to provide a questionnaire before and after travelling, as well after 2, 4, 6, 8, 10, 12, 16, 20 and 52 weeks.</description>
    <arm_group_label>travellers to Southeast Asia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>examination of blood sample</intervention_name>
    <description>Each participant will have to provide a blood sample before and after travelling and after 6, 12 and 20 weeks. A serum sample (5mL) for antibody measurement and a 50 ml blood sample for recovery of peripheral blood mononuclear cells (PBMCs in 6 CPTs) for cell mediated immunity will be collected. Serum and PBMCs will allow the analysis of anti-E. coli humoral and cellular responses in order to characterize the individual immune response to specific bacteria over time. Single nucleotide polymorphisms associated with humoral and cellular immune responses will be characterized and linked to immunological and clinical phenotypes and endpoints of the study.</description>
    <arm_group_label>travellers to Southeast Asia</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Bacterial isolates and -80°C stool samples. Serum samples and blood cells may be used for&#xD;
      antibody analysis and blood cell analysis (incl. B-cell immortalization for monoclonal&#xD;
      antibody generation).&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Clients planning to travel to Southeast Asia will be recruited while receiving pre-travel&#xD;
        health advice at the travel clinic of the Swiss Tropical and Public Health Institute in&#xD;
        Basel.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  travelling to Southeast Asia (India, Bhutan, Nepal, Bangladesh, Myanmar, Thailand,&#xD;
             Laos, Cambodia, Vietnam) for a maximum of 4 weeks.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  other travelling destinations than mentioned above&#xD;
&#xD;
          -  antibiotic use at the first sampling time&#xD;
&#xD;
          -  Participants who are not colonized will serve as a control group for microbiome&#xD;
             comparison&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian Egli, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Clinical Microbiology, University Hospital Basel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Basel, Division of Clinical Microbiology</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 17, 2021</study_first_submitted>
  <study_first_submitted_qc>February 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antibiotic resistance</keyword>
  <keyword>pan-sensitive strains (non-ESBL E. coli)</keyword>
  <keyword>multidrug resistant E. coli strains</keyword>
  <keyword>ESBL E. coli displacement</keyword>
  <keyword>multidrug resistant Enterobacteriaceae</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

